8th EPITA Symposium & 37th AIDPIT Workshop
Novo Nordisk is a global healthcare company with more than 90 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat other serious chronic diseases: haemophilia, growth disorders and obesity. Our ambition is to take the lead in each of these areas, driving change with an unfailing belief that it can be done.
Learn more at novonordisk.com/about-novo-nordisk
Innovative medicine is our key contribution
Our key contribution is to discover and develop better biological medicines, manufacture them to meet increasing global demand and make them accessible wherever they are needed. In 2016, Novo Nordisk invested 13% of its sales in R&D, and around 25,300 people took part in 125 clinical trials across approximately 5,100 clinical sites globally. Our current pipeline includes new insulins and GLP-1 analogues, and new treatments for haemophilia, obesity and other areas.
Learn more at novonordisk.com/rnd.html
Changing lives with devices
In the 1980s, it was recognised that multiple daily insulin injections could help people with diabetes gain better control of their blood sugar levels. Launched in 1985 and resembling a fountain pen, NovoPen® was the world’s first device to offer people with diabetes a simple means of injecting themselves with precisely the right dose of insulin several times a day. Novo Nordisk’s pens have been recognized for their innovative designs, winning the 1986 Industrial Design Award, the 2010 US Good Design™ Award and the prestigious Red Dot ‘Best of the Best’ prize in 2012.
Learn more at novonordisk.com/patients/diabetes-care.html
Triple Bottom Line approach to business
To ensure we continue helping people affected by serious chronic diseases, our business needs to grow both profitably and responsibly. We call this approach the Triple Bottom Line. It means Novo Nordisk is committed to considering the financial, social and environmental impacts of every decision as we work to create value for individuals, society and investors.
Learn more at novonordisk.com/sustainability
Unique ownership structure
The Novo Nordisk Foundation is Novo Nordisk’s main shareholder. The foundation’s purpose is to provide a stable basis for the commercial and research activities of the Novo Group of companies, and also to support scientific and humanitarian projects. This unique ownership structure protects Novo Nordisk against hostile takeovers, enables long-term planning and ensures that the company remains in Danish ownership.
Learn more at novonordiskfonden.dk/en
Life is a health journey, with ups and downs, which can be big or small, lifelong or momentary.
We, at Sanofi, are there for those challenges, as a health journey partner. Many patients are depending on us. We aim to protect, enable and support people facing health challenges, so they can live life to its full potential.
Sanofi, Empowering Life.
Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on rare diseases, multiple sclerosis, immunology, and oncology. We help people with debilitating and complex conditions that are often difficult to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world.
Genzyme became part of Sanofi in 2011. While continuing to focus on rare diseases, we also established ourselves as a leader in the field of multiple sclerosis. In 2016, our focus expanded to include Sanofi’s programs in oncology and immunology.
Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Founded as Genzyme in Boston in 1981, we rapidly grew to become one of the world’s leading biotechnology companies, recognized for our pioneering development of treatments for rare genetic disorders and our innovative contributions to medical science and biomanufacturing.
Our ambition is to be the industry leader in specialty care. We currently provide more than 20 treatments to patients globally, with many potential new therapies being studied in clinical trials and in Sanofi laboratories.
Driven by our commitment to patients, we strive to develop strong relationships with patient communities and listen to their perspectives so that we can truly understand their needs. These collaborations guide us as we continue to push the boundaries of medicine and technology to develop new and better therapies where none existed before.
Sanofi Genzyme's dedication to patients extends beyond the development of products. We've initiated numerous free drug, payment assistance, and humanitarian programs to ensure that vital treatment reaches all those who need it.
We're also committed to responsible corporate citizenship: we lead the industry in environmental initiatives and support local communities through grants and our employees’ volunteer efforts.
Roche´s products and services help to prevent, diagnose and treat diseases, thereby enhancing people’s health and quality of life. For over a century, the Roche name has stood for innovative, high-quality products and services.
Building on over 30 years of industry experience, Roche CustomBiotech uses the powerful multidisciplinary skills found in Roche facilities across the world. Our team offers products and solutions for manufacturers in the diagnostics and pharma biotech industry ranging from substances to system solutions for bioprocessing. Our extensive product portfolio spans the breadth of the industry, from enzymes and cofactors, substrates, customized kits and PCR-based kits for rapid microbiological methods for Quality Control. Furthermore we offer analyzers for cell growth monitoring and fermentation process monitoring.
Now more than ever, business success hinges on finding suppliers, collaborators, and other partners who understand your needs and allow you to focus on what matters. A market leader with decades of experience in biotechnology and in vitro diagnostics will be happy to stand shoulder to shoulder with your team.